Barclays’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-82,690
| Closed | -$1.57M | – | 7608 |
|
|
2019
Q1 | $1.57M | Buy |
82,690
+47,652
| +136% | +$773K | ﹤0.01% | 2863 |
|
|
2018
Q4 | $473K | Buy |
35,038
+34,891
| +23,735% | +$390K | ﹤0.01% | 3864 |
|
|
2018
Q3 | $2K | Buy |
+147
| New | +$1.47K | ﹤0.01% | 6991 |
|
|
2017
Q1 | – | Sell |
-9,377
| Closed | -$45K | – | 7272 |
|
|
2016
Q4 | $45K | Buy |
9,377
+5,228
| +126% | +$26.8K | ﹤0.01% | 5241 |
|
|
2016
Q3 | $20K | Buy |
4,149
+2,290
| +123% | +$11.7K | ﹤0.01% | 5485 |
|
|
2016
Q2 | $9K | Sell |
1,859
-33,162
| -95% | -$179K | ﹤0.01% | 5605 |
|
|
2016
Q1 | $175K | Sell |
35,021
-506
| -1% | -$3.53K | ﹤0.01% | 3935 |
|
|
2015
Q4 | $356K | Buy |
35,527
+21,094
| +146% | +$286K | ﹤0.01% | 3466 |
|
|
2015
Q3 | $260K | Sell |
14,433
-6,548
| -31% | -$126K | ﹤0.01% | 3941 |
|
|
2015
Q2 | $399K | Buy |
20,981
+17,570
| +515% | +$311K | ﹤0.01% | 3654 |
|
|
2015
Q1 | $59K | Sell |
3,411
-7,258
| -68% | -$122K | ﹤0.01% | 5186 |
|
|
2014
Q4 | $160K | Sell |
10,669
-34,406
| -76% | -$461K | ﹤0.01% | 4820 |
|
|
2014
Q3 | $540K | Buy |
45,075
+28,748
| +176% | +$410K | ﹤0.01% | 3885 |
|
|
2014
Q2 | $245K | Sell |
16,327
-8,376
| -34% | -$123K | ﹤0.01% | 4642 |
|
|
2014
Q1 | $321K | Buy |
24,703
+3,230
| +15% | +$50.5K | ﹤0.01% | 4336 |
|
|
2013
Q4 | $343K | Sell |
21,473
-7,419
| -26% | -$118K | ﹤0.01% | 4457 |
|
|
2013
Q3 | $462K | Buy |
28,892
+6,416
| +29% | +$94.9K | ﹤0.01% | 4202 |
|
|
2013
Q2 | $227K | Buy |
+22,476
| New | +$236K | ﹤0.01% | 5041 |
|
Other funds holding OSIR
Barclays's OSIR Position: Q2 2019 in Review
Barclays sold out of Osiris Therapeutics, Inc. Common Stock (OSIR) in Q2 2019, closing a stake of 82,690 shares — an estimated $1.57M sold.
Barclays first reported a position in OSIR in Q2 2013 and held it in 18 quarters. The position peaked at $1.57M in Q1 2019. 1 fund tracked by Wall St. Rank holds OSIR as of Q2 2019.
- Barclays reported no remaining Osiris Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
- Barclays sold 82,690 Osiris Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $1.57M.
- Barclays first reported a position in Osiris Therapeutics, Inc. Common Stock in Q2 2013 and held it in 18 quarters.
- Barclays's Osiris Therapeutics, Inc. Common Stock position peaked at $1.57M in Q1 2019.
- 1 fund tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q2 2019.
Based on Barclays's 13F filing for Q2 2019, filed 14 Aug 2019.